Taysha Gene Therapy trial gets green light from Health Canada

On 29th March 2022, Taysha Gene Therapies announced that they have now received approval from Health Canada, to start the first gene therapy trial for their Rett product TSHA-102 in Canada, in a small group of adult women with Rett Syndrome.

The work leading up to this trial was financially supported by Reverse Rett, via regular contributions to the RSRT Gene Therapy Consortium. We extend our deepest gratitude to all the fundraisers and supporters who have enabled us to reach this point in time.

You can read the full announcement from Taysha here.

Read Taysha’s letter to the Rett community re the announcement here.

“Today’s CTA clearance is a pivotal moment for the Rett community, and it would not have been
possible without the tireless work of my Taysha Colleagues, our partners at UTSW, the Rett Clinical
and Scientific experts with whom we collaborate, and most importantly the Rett syndrome
community. Initiation of a clinical trial is a formative moment, and we are motivated by the
patients and families whom we serve and the potential of TSHA-102. Thank you to the patient
advocacy leaders for your partnership and the patients and caregivers for your continued support.”

-Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM,
Pediatrician, Chief Medical Officer and Head of Research & Development at Taysha Gene Therapies